New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:52 EDTREGNRegeneron upgraded to Buy from Neutral at Citigroup
Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use